Literature DB >> 25322705

Candida parapsilosis sensu stricto and the closely related species Candida orthopsilosis and Candida metapsilosis in vulvovaginal candidiasis.

Yuxia Zhu1, Yingying Shan, Shangrong Fan, Jianling Li, Xiaoping Liu.   

Abstract

This study aimed to determine the clinical characteristics and in vitro susceptibilities of Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis isolates from patients with vulvovaginal candidiasis (VVC). We analysed 63 vaginal C. parapsilosis specimens. After the molecular analyses, the isolates were characterised as C. parapsilosis sensu stricto (77.8%), C. orthopsilosis (7.9%) and C. metapsilosis (14.3%). The signs and symptoms of VVC caused by C. parapsilosis sensu lato, including itching, erythema and abnormal discharge, were milder than those caused by C. albicans. None of the C. parapsilosis sensu lato isolates were resistant to fluconazole, miconazole or itraconazole. The resistance rates of C. albicans to fluconazole, itraconazole, miconazole and clotrimazole were 2.3, 1.5, 3.1 and 0.8%, respectively. Both C. parapsilosis sensu lato and C. albicans were susceptible to nystatin. The mycological eradication rate at follow-up days 7-14 and 30-35 were 77.8% (49/63) and 76.2% (48/63), respectively, when treated with various antifungal agents and regimens. We conclude that C. parapsilosis sensu stricto and the closely related species C. orthopsilosis and C. metapsilosis were present in the vaginal samples of VVC patients. The symptoms and signs of VVC caused by C. parapsilosis are milder than those caused by C. albicans. The antifungal susceptibility and therapeutic efficacy in patients colonised by C. parapsilosis sensu lato were similar to those observed in C. albicans-colonised patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25322705     DOI: 10.1007/s11046-014-9821-x

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  29 in total

1.  Prevalence and distribution profiles of Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis responsible for superficial candidiasis in a Chinese university hospital.

Authors:  Xiaobo Feng; Bo Ling; Guimei Yang; Xia Yu; Daming Ren; Zhirong Yao
Journal:  Mycopathologia       Date:  2011-11-19       Impact factor: 2.574

2.  Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy.

Authors:  Deepti Goswami; Ravinder Goswami; Uma Banerjee; Vatsla Dadhwal; Sunita Miglani; Ali Abdul Lattif; Narayana Kochupillai
Journal:  J Infect       Date:  2006-02       Impact factor: 6.072

3.  Sexually transmitted diseases treatment guidelines, 2010.

Authors:  Kimberly A Workowski; Stuart Berman
Journal:  MMWR Recomm Rep       Date:  2010-12-17

4.  Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital.

Authors:  Ilargi Miranda-Zapico; Elena Eraso; José Luis Hernández-Almaraz; Leyre Mónica López-Soria; Alfonso Javier Carrillo-Muñoz; Juan Manuel Hernández-Molina; Guillermo Quindós
Journal:  J Antimicrob Chemother       Date:  2011-07-26       Impact factor: 5.790

5.  Molecular epidemiology and antifungal susceptibility of Candida parapsilosis sensu stricto, Candida orthopsilosis, and Candida metapsilosis in Taiwan.

Authors:  Yee-Chun Chen; Yu-Hsin Lin; Kuo-Wei Chen; Joanne Lii; Hwa-Jen Teng; Shu-Ying Li
Journal:  Diagn Microbiol Infect Dis       Date:  2010-09-20       Impact factor: 2.803

6.  Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III.

Authors:  Arianna Tavanti; Amanda D Davidson; Neil A R Gow; Martin C J Maiden; Frank C Odds
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

7.  Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain.

Authors:  A Gomez-Lopez; A Alastruey-Izquierdo; D Rodriguez; B Almirante; A Pahissa; J L Rodriguez-Tudela; M Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

Review 8.  Vulvovaginal candidosis.

Authors:  Jack D Sobel
Journal:  Lancet       Date:  2007-06-09       Impact factor: 79.321

9.  Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil.

Authors:  S S Gonçalves; C S Amorim; M Nucci; A C B Padovan; M R S Briones; A S A Melo; A L Colombo
Journal:  Clin Microbiol Infect       Date:  2009-08-17       Impact factor: 8.067

10.  Three distinct genotypes within Candida parapsilosis from clinical sources.

Authors:  D Lin; L C Wu; M G Rinaldi; P F Lehmann
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

View more
  4 in total

Review 1.  Candida parapsilosis Vaginal Infection-a New Site of Azole Drug Resistance.

Authors:  J D Sobel; S Suprapaneni
Journal:  Curr Infect Dis Rep       Date:  2018-08-27       Impact factor: 3.725

Review 2.  Distribution and antifungal susceptibility pattern of Candida species from mainland China: A systematic analysis.

Authors:  Hazrat Bilal; Muhammad Shafiq; Bing Hou; Rehmat Islam; Muhammad Nadeem Khan; Rahat Ullah Khan; Yuebin Zeng
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

3.  Simple, Low-Cost Detection of Candida parapsilosis Complex Isolates and Molecular Fingerprinting of Candida orthopsilosis Strains in Kuwait by ITS Region Sequencing and Amplified Fragment Length Polymorphism Analysis.

Authors:  Mohammad Asadzadeh; Suhail Ahmad; Ferry Hagen; Jacques F Meis; Noura Al-Sweih; Ziauddin Khan
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

4.  Phytol-Loaded Solid Lipid Nanoparticles as a Novel Anticandidal Nanobiotechnological Approach.

Authors:  Tábata L C Lima; Luanda B F C Souza; Lannya C S Tavares-Pessoa; Alaine M Dos Santos-Silva; Rômulo S Cavalcante; Raimundo F de Araújo-Júnior; Alianda M Cornélio; Matheus F Fernandes-Pedrosa; Guilherme Maranhão Chaves; Arnóbio Antônio da Silva-Júnior
Journal:  Pharmaceutics       Date:  2020-09-13       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.